Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total transaction of $594,395.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $116.00, for a total transaction of $2,900,000.00.
  • On Friday, July 28th, Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $114.68, for a total transaction of $607,804.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00.

Shares of Edwards Lifesciences Corporation (NYSE:EW) opened at 113.31 on Friday. Edwards Lifesciences Corporation has a 52 week low of $81.12 and a 52 week high of $121.75. The stock has a market cap of $23.93 billion, a PE ratio of 34.37 and a beta of 0.64. The company’s 50-day moving average is $115.12 and its 200 day moving average is $107.54.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.88 by $0.20. The company had revenue of $842 million during the quarter, compared to analysts’ expectations of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.76 earnings per share. Analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) VP Sells $594,395.00 in Stock” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/09/02/edwards-lifesciences-corporation-ew-vp-sells-594395-00-in-stock.html.

Several equities research analysts have commented on the stock. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 13th. Canaccord Genuity reaffirmed a “buy” rating and issued a $150.00 price target on shares of Edwards Lifesciences Corporation in a report on Wednesday, June 28th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price target on the stock in a report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on shares of Edwards Lifesciences Corporation in a report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price target on the stock. Finally, Cowen and Company reaffirmed an “outperform” rating and issued a $135.00 price target (up from $130.00) on shares of Edwards Lifesciences Corporation in a report on Thursday, July 27th. Six equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. Edwards Lifesciences Corporation has an average rating of “Buy” and an average target price of $120.75.

A number of institutional investors have recently made changes to their positions in EW. Lord Abbett & CO. LLC boosted its position in shares of Edwards Lifesciences Corporation by 58.4% in the second quarter. Lord Abbett & CO. LLC now owns 83,718 shares of the medical research company’s stock worth $9,899,000 after buying an additional 30,875 shares during the last quarter. Toronto Dominion Bank boosted its position in shares of Edwards Lifesciences Corporation by 24.0% in the second quarter. Toronto Dominion Bank now owns 71,106 shares of the medical research company’s stock worth $8,406,000 after buying an additional 13,747 shares during the last quarter. Advisory Services Network LLC boosted its position in shares of Edwards Lifesciences Corporation by 0.9% in the second quarter. Advisory Services Network LLC now owns 12,565 shares of the medical research company’s stock worth $1,486,000 after buying an additional 112 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Edwards Lifesciences Corporation by 14.2% in the second quarter. Public Employees Retirement System of Ohio now owns 361,650 shares of the medical research company’s stock worth $42,761,000 after buying an additional 44,877 shares during the last quarter. Finally, Covington Capital Management boosted its position in shares of Edwards Lifesciences Corporation by 28.7% in the second quarter. Covington Capital Management now owns 9,983 shares of the medical research company’s stock worth $1,180,000 after buying an additional 2,225 shares during the last quarter. Institutional investors own 82.36% of the company’s stock.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.